


What is claimed is:

1. A compound represented by the formula:



5 wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring B is benzene ring which is further substituted, Ring C is a dihydrofuran ring which may be further substituted and R is hydrogen atom
10 or an acyl group, or a salt thereof.

2. The compound according to Claim 1, wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted by an optionally substituted hydrocarbon
15 group.

3. The compound according to Claim 1, wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted by an optionally substituted lower alkyl
20 group.


4. The compound according to Claim 1, wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further

1.0069180.021502

substituted by a lower alkyl group.

5. The compound according to Claim 1, wherein Ring A is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted by a lower alkyl group.

6. The compound according to Claim 1 which is represented by the formula:



wherein R^4 and R^5 are the same or different and each denotes hydrogen atom, a halogen atom, hydroxy group group, amino group or a hydrocarbon group which may be bonded directly or via oxygen atom, nitrogen atom or sulfur atom and which may be substituted, and the other symbols are as defined in Claim 1, provided that both R^4 and R^5 are not hydrogen atoms at the same time, or a salt thereof.


7. The compound according to Claim 6, wherein R^4 and R^5 are the same or different and each denotes a lower alkyl group or a lower alkoxy group.

8. The compound according to Claim 6, wherein each of R^4 and R^5 is a lower alkyl group.

Sub.
Q76

1.0069180-021502

9. The compound according to Claim 4 which is represented by the formula:



wherein R^1 and R^2 are the same or different and each denotes hydrogen atom, an optionally esterified or amidated carboxyl group or an optionally substituted hydrocarbon group, R^3 is hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted amino group, and the other symbols are as defined in Claim 5, or a salt thereof.

10. The compound according to Claim 9, wherein R^1 is a lower alkyl group, R^2 is a lower alkyl group which may be substituted by a halogen atom, hydroxy group or an optionally substituted cyclic amino group and R^3 is hydrogen atom or an optionally substituted phenyl group.

11. The compound according to Claim 9, wherein R^1 is a lower alkyl group, R^2 is a lower alkyl group which may be substituted by a halogen atom, hydroxy group or an optionally substituted cyclic amino group, R^3 is hydrogen atom or an optionally substituted phenyl group, each of R^4 and R^5 is a lower alkyl group, and Ring A is

a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted by a lower alkyl group.

12. The compound according to Claim 9, wherein R¹ is a lower alkyl group, R² is a lower alkyl group which may be substituted by a halogen atom, hydroxy group or optionally substituted cyclic amino group, R³ is hydrogen atom or an optionally substituted phenyl group, each of R⁴ and R⁵ is a lower alkyl group, and Ring A is a non-aromatic 5-membered nitrogen-containing heterocyclic ring which may be further substituted by a lower alkyl group.

13. The compound according to Claim 1 which is 8-tert-butyl-3,5,6,7-tetrahydro-2,2,4,6,6-pentamethyl-2H-furo[2,3-f]indole or a salt thereof.

14. The compound according to Claim 1 which is 3,5,6,7-tetrahydro-2,4,8-trimethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[2,3-f]indole or a salt thereof.

15. The compound according to Claim 1 which is 3,5,6,7-tetrahydro-2,4,6,6,8-pentamethyl-2-[(4-phenylpiperidino)methyl]-2H-furo[2,3-f]indole or a salt thereof.


16. The compound according to Claim 1 which is 3,5,6,7-tetrahydro-2,2,4,8-tetramethyl-3-(4-

10069180-021502

methylphenyl)-2H-furo[2,3-f]indole or a salt thereof.


17. A prodrug of the compound according to Claim 1.

18. A process for preparing the compound according to Claim 1 or a salt thereof which comprises subjecting a substituent X and hydroxy group on Ring B of a compound represented by the formula:



wherein X is an optionally substituted allyl group, and the other symbols are as defined in Claim 1 or a salt thereof to a ring-closure reaction.

19. A pharmaceutical composition comprising a compound represented by the formula:




wherein Ring A is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring B is benzene ring which is further substituted, Ring C is a dihydrofuran ring which may be further substituted and R is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof.

Sub.
a 77

10069130.021502


20. A prophylactic and therapeutic agent against a cerebrovascular impairment, a cranial trauma or a neurodegenerative disease comprising a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof.

21. The prophylactic and therapeutic agent according to Claim 20, wherein said neurodegenerative disease is Parkinson's disease or Alzheimer's disease.

22. A prophylactic and therapeutic agent against a dysuria or a urinary incontinence comprising a compound represented by the formula:




wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be

205120-08T6900T


further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof.

23. A prophylactic and therapeutic agent against a restenosis after a percutaneous transluminal coronary angioplasty comprising a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof.

24. A lipid peroxidation inhibitor comprising a compound represented by the formula:




wherein Ring Aa is a non-aromatic 5- to 7-membered

205720-08T5900T


nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof.

25. A method for preventing or treating a cerebrovascular impairment, a cranial trauma or a neurodegenerative disease which comprises administering a compound represented by the formula:




wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof to a mammal.

26. A method for preventing or treating a dysuria or a urinary incontinence which comprises administering a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof to a mammal.


27. A method for preventing or treating a restenosis after a percutaneous transluminal coronary angioplasty which comprises administering a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered nitrogen-containing heterocyclic ring which may be further substituted, Ring Ba is benzene ring which may be further substituted, Ring Ca is a dihydrofuran ring which may be further substituted and Ra is hydrogen atom or an acyl group, or a salt thereof or a prodrug thereof to a mammal.


28. A method for inhibiting lipid peroxidation

which comprises administering an effective amount of a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered
 5 nitrogen-containing heterocyclic ring which may be
 further substituted, Ring Ba is benzene ring which may
 be further substituted, Ring Ca is a dihydrofuran ring
 which may be further substituted and Ra is hydrogen
 atom or an acyl group, or a salt thereof or a prodrug
 10 thereof to a mammal.


29. Use of a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered
 nitrogen-containing heterocyclic ring which may be
 15 further substituted, Ring Ba is benzene ring which may
 be further substituted, Ring Ca is a dihydrofuran ring
 which may be further substituted and Ra is hydrogen
 atom or an acyl group, or a salt thereof or a prodrug
 thereof for manufacturing a prophylactic and
 20 therapeutic agent against a cerebrovascular impairment,
 a cranial trauma or a neurodegenerative disease.


205F20-08T6900F 10069180-021502

30. Use of a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered
nitrogen-containing heterocyclic ring which may be
5 further substituted, Ring Ba is benzene ring which may
be further substituted, Ring Ca is a dihydrofuran ring
which may be further substituted and Ra is hydrogen
atom or an acyl group, or a salt thereof or a prodrug
thereof for manufacturing a prophylactic and
10 therapeutic agent against a dysuria or a urinary
incontinence.

31. Use of a compound represented by the formula:




wherein Ring Aa is a non-aromatic 5- to 7-membered
15 nitrogen-containing heterocyclic ring which may be
further substituted, Ring Ba is benzene ring which may
be further substituted, Ring Ca is a dihydrofuran ring
which may be further substituted and Ra is hydrogen
atom or an acyl group, or a salt thereof or a prodrug
20 thereof for manufacturing a prophylactic and
therapeutic agent against a restenosis after a

205T20-081502

percutaneous transluminal coronary angioplasty.

32. Use of a compound represented by the formula:



wherein Ring Aa is a non-aromatic 5- to 7-membered
5 nitrogen-containing heterocyclic ring which may be
further substituted, Ring Ba is benzene ring which may
be further substituted, Ring Ca is a dihydrofuran ring
which may be further substituted and Ra is hydrogen
atom or an acyl group, or a salt thereof or a prodrug
10 thereof for manufacturing a lipid peroxidation
~~inhibitor.~~

10069180-024502